Since then, the published experience with biologics during pregnancy mainly deals with the use of TNFα inhibitors (TNFα-i) (Flint et al., 2016; Skorpen et al., 2016; Østensen, 2017); data from a growing number of publications on the use of TNFα-i pregnant women with most autoimmune diseases is reassuring (Smeele and Dolhain, 2019). This evidence concerns the gene TNF and autoimmune disease.